• The biotech company, led by Galician scientists, helps pharmaceutical and biotechnology companies develop therapies to treat obesity, diabetes, non-alcoholic fatty liver or oxidative stress
  • The biotechnology firm based in Santiago expands its business areas towards oncology and neurodegenerative diseases
  • Albor Biotech consolidates a workforce, considered “its main strategic asset”, made up of five qualified researchers

Santiago de Compostela. 01/27/2026. Albor Biotech, a spin-off from the University of Santiago de Compostela (USC) and strategic partner in the development of new therapeutic solutions, celebrates its first year of activity this January. On the occasion of this milestone, its promoters take stock and highlight that Albor Biotech is consolidating itself as a CRO (Contract Research Organization) company specialized in offering specialized research and development services for preclinical trials with therapeutic purposes aimed at the pharmaceutical and biotechnology industry in the field of metabolism, oncology and neurodegenerative disorders. “Our results are far above the forecasts collected in the initial business plan”, they emphasize.

Albor Biotech, a member of the Business Technology Cluster of Life Sciences (Bioga), is led in the scientific field by Galician researchers Rubén Nogueiras Pozo and Uxía Fernández Paz, and by David Calvo, an expert in start-up management, who serves as CEO. “In this first year we managed to exceed the goals set, both in volume of activity and in positioning in the market”, highlights Calvo, who points out that the company “achieved a positive result in this first year, a relevant milestone in science-based biotech firms”.

70 percent of Albor Biotech’s customers are from third countries, mainly from the European Union. “We work with pharmaceutical companies and research groups from different European countries”, says Uxía Fernández Paz, scientific director of the biotech. “By consolidating our portfolio of international clients, we managed to strengthen our international vocation and validate our scientific proposal in a competitive environment”.

Talent transfer
Albor Biotech also bets on talent and its transfer to the market. In its first year, the company consolidated a workforce of qualified professionals, mostly with PhDs. “They have specialized scientific and technical profiles”, highlights Uxía Fernández Paz, who adds that this team “constitutes the core of our operational capacity; it is our main strategic asset”.

“The balance of the first year of Albor Biotech’s life confirms that there is a real demand for highly specialized preclinical services and that a project built on scientific rigor, flexibility and closeness to the client can grow solidly from its birth”, say the management of the company, which has the support of the Galician Innovation Agency (GAIN).

Albor Biotech sets future goals for the coming years. “This new stage will be focused on consolidating our positioning, progressively expanding our capabilities and strengthening our presence in international markets”, says David Calvo. “We want to maintain sustained growth and aligned with the standards of scientific excellence that define the company”, Uxía Fernández Paz also remarks.

More about Albor Biotech
Albor Biotech is a spin-off of the University of Santiago de Compostela (USC) that reflects the commitment of this academic institution to the transfer of knowledge and the promotion of innovative business initiatives. Led by a prestigious scientific team, the new company receives support from the Galician Innovation Agency (GAIN) and combines cutting-edge technologies and advanced methodologies to offer high-quality services to the pharmaceutical and biotechnology industry.

+ info: www.alborbiotech.com Communication Office Bioga. 679.486.961.